NC
NBIX icon

Nexthera Capital’s Neurocrine Biosciences NBIX Stock Holding History

Nexthera Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$7.8M Buy
92,380
+68,340
+284% +$5.61M 6.5% 4
2019
Q1 		$2.12M Buy
+24,040
New +$2.01M 2.57% 15
2017
Q1 		– Sell
-120,000
Closed -$4.64M – 44
2016
Q4 		$4.64M Buy
+120,000
New +$5.43M 2.72% 13
2016
Q2 		– Sell
-42,000
Closed -$1.66M – 38
2016
Q1 		$1.66M Buy
42,000
+15,000
+56% +$595K 1.72% 15
2015
Q4 		$1.53M Buy
+27,000
New +$1.37M 2.17% 11

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nexthera Capital's NBIX Position: Q2 2019 in Review

Nexthera Capital increased its Neurocrine Biosciences (NBIX) stake by 284% in Q2 2019, buying an estimated $5.61M and bringing the position to 92,380 shares worth $7.8M. The position accounts for 6.5% of the portfolio, ranked #4.

Nexthera Capital first reported a position in NBIX in Q4 2015 and has held it in 5 quarters since. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • Nexthera Capital held 92,380 shares of Neurocrine Biosciences worth $7.8M as of Q2 2019.
  • Nexthera Capital bought 68,340 Neurocrine Biosciences shares in Q2 2019, an estimated $5.61M.
  • Neurocrine Biosciences made up 6.5% of Nexthera Capital's portfolio in Q2 2019, its #4 holding.
  • Nexthera Capital first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 5 quarters since.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.